Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Pharmacogenetics is being used to develop personalized therapies specific to subjects from
different ethnic or racial groups. To date, pharmacogenetic studies have been primarily …

Summary Background The Single combination budesonide–formoterol inhaler Maintenance
And Reliever Therapy (SMART) regimen reduces severe asthma exacerbations in patients …

Background Concerns remain about the safety of adding long-acting β2-agonists to inhaled
glucocorticoids for the treatment of asthma. In a postmarketing safety study mandated by the …

Background: There is concern that long-acting β agonist (LABA) drugs may increase the risk
of asthma mortality. Methods: A meta-analysis was conducted of asthma deaths in …

Background Combination therapy with an inhaled corticosteroid (ICS) and long-acting β2
agonist (LABA) is recommended for patients with asthma symptomatic on ICS alone …

BACKGROUND: It is unclear whether long-acting β-agonists with concomitant inhaled
corticosteroids increase asthma-related intubations and deaths. We pooled data on long …

Inhaled β 2-adrenoceptor (β 2-AR) agonists are considered essential bronchodilator drugs
in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with …

Asthma is a very common respiratory condition with a worldwide prevalence predicted to
increase. There are significant differences in airway epithelial responses in asthma that are …

Human genetics research will be critical to the development of genetic profiles for
personalized or precision medicine in asthma. Genetic profiles will consist of gene variants …